Authors
Latest:
FDA Approves Gilead’s Twice-Yearly Injectable Lenacapavir (Yeztugo) for HIV PreventionGilead’s Yeztugo, a long-acting HIV capsid inhibitor, shows 96 to 100% efficacy in phase 3 trials and aims to expand access worldwide through regulatory filings and support programs.
Latest:
What is Driving the Global Expansion of Lyme Disease?Climate-driven changes and other drivers of the expanding geographic range of Ixodes ticks and Lyme disease are explored.
Latest:
Improving Quality of Life For Those With Recurrent C DifficilePaul Feuerstadt, MD, FACG, AGAF, offers a glimpse of patients dealing with this and insights on improving patients’ quality of life, post-treatment with fecal microbiota, live-jslm (Rebyota [RBL]).
Latest:
Echinocandin Dosing Considerations in Obese Patients: A ReviewObesity significantly impacts the pharmacokinetics (PK) of antifungal drugs like echinocandins, including volume of distribution (Vd) and clearance. However, despite these PK differences, current clinical evidence generally does not support the need for universal dose adjustments in obese patients. Clinicians should consider personalized dosing based on patient characteristics, infection severity, and specific drug properties due to echinocandins' favorable safety profiles.
Latest:
COVID-19 Impact on Antimicrobial Stewardship: Consequences and Silver LiningsThis crisis has united multidisciplinary groups and laid the foundation to better equip the health care workforce for future pandemics.
Latest:
Combination Hepatitis C Therapy Efficacious in Those With Previously Untreated Acute InfectionTreatment with glecaprevir/pibrentasvir (G/P) demonstrated a virologic response at post-treatment week 12, which was superior to the prior efficacy threshold.
Latest:
Starting an Inpatient Penicillin Skin Testing Service in 2023Patients with a penicillin allergy can be safely delabeled using minimal resources, opening up treatment options.
Latest:
INSPIRE Trials: Reducing Antibiotic Prescribing For Skin and Soft Tissue And Abdominal InfectionsLed by Shruti K. Gohil, MD, MPH, the trials examined how computerized physician order entry prompts can reduce the use of extended-spectrum antibiotics in hospitalized patients while maintaining patient safety.
Latest:
Infectious Diseases Provider Role in Extracorporeal Membrane Oxygenation InfectionsThere has been an emergence of extracorporeal membrane oxygenation-associated infections. Here is a review of how to define them and clinical management of this heterogeneous syndrome.
Latest:
All About the JUICE: Justifying Use of Non-Carbapenems for Infected NeCrotizing PancrEatitisManagement of this condition has been associated with antibiotic misuse. In the latest Bench to Bedside column, clinicians offer insights on therapy indications and what the latest literature reports on the condition.
Latest:
The Role of Rifampin in Bone and Joint InfectionsIn the latest column from the Society of Infectious Diseases Pharmacists (SIDP), here is a discussion on the use of rifampin as an adjunctive antibiotic treatment for patients with diabetic foot osteomyelitis.
Latest:
What You Need to Know About 3 Rare Infectious Eye DiseasesEric D. Donnenfeld, MD, discusses 3 uncommon yet highly infectious eye diseases, emphasizing the importance of timely treatment and preventative measures.
Latest:
What’s New With Non–COVID-19 VaccinesAlthough COVID-19 vaccination remains the primary focus for health care, other paramount vaccines need to be recognized. Here is a review.
Latest:
Fluoroquinolone Safe for Treating Severe Refractory M Pneumoniae PneumoniaInvestigators asked the children’s parents about the history of musculoskeletal-related disease, observed the children’s gait, and performed physical examinations.
Latest:
Clinicians Discuss the State of Vaccines TodayA panel discusses how vaccine policy under new federal government policies, why misinformation has flourished and what individual providers can do to win back patient trust.
Latest:
Barriers to Health Care Transition in Adolescents and Young Adults With Early Acquired HIV InfectionUnique challenges can affect the success of the shift from pediatric to adult care settings.
Latest:
Novavax Seeks Full FDA Approval for COVID-19 VaccineRobert Walker, MD discussed the company's application for full licensure and the importance of vaccination.
Latest:
Multidisciplinary Perspectives on HIV TreatmentA multidisciplinary panel concludes a discussion on best practices for managing patients with HIV in various healthcare settings and overcoming social health disparities.
Latest:
Clinicians Discuss the State of Vaccines TodayA panel discusses how vaccine policy under new federal government policies, why misinformation has flourished and what individual providers can do to win back patient trust.
Latest:
What We Know But Still Have to Learn About Long COVIDDespite advances in understanding and treating Long COVID, many questions about its mechanisms, susceptibility, and varied recovery patterns remain unresolved, underscoring the need for continued research.
Latest:
Resources Available for Patients with HIV Drug ResistanceThe panel concludes its discussion by talking about resources available for providers in managing their patients with HIV who experience drug resistance.
Latest:
Examining RSV Vaccines for SeniorsTwo RSV vaccines for seniors were FDA approved this year and here is an overview of the vaccines and the study data.
Latest:
When Should We De-Escalate Empiric Antimicrobials?De-escalating empiric antimicrobial therapy is a strategy to combat antimicrobial resistance. Antimicrobial stewardship programs can play a major role in preserving antibiotic effectiveness and preventing unnecessary antibiotic use.
Latest:
Expanding HIV Prevention: Overcoming Barriers and Embracing Long-Acting PrEPZandraetta Tims-Cook, MD, MPH, highlights the need for inclusive HIV prevention strategies and discusses the potential of long-acting injectable PrEP in improving care and reducing disparities.
Latest:
IDSA Guidance on the Treatment of Antimicrobial Resistant Gram-Negative InfectionsSince late 2004, 7 novel antibiotics with activity against ESBL-E, CRE, and/or DTR P aeruginosa have been approved.
